MedTrace Logo

Antipsychotic Effects of Oxytocin

NCT01621737 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2019-11-19

Study results available
· View outcomes & findings →

Summary

The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with antipsychotic medication.

Conditions

Interventions

DRUG

Oxytocin

42 IU BID for six weeks

DRUG

Oxytocin

84 IU BID for six weeks

DRUG

Placebo

Vehicle placebo

Sponsors & Collaborators

Principal Investigators

  • David Feifel, MD, Ph.D · UCSD

  • Steven Potkin, MD · UCI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01621737 on ClinicalTrials.gov